Free Trial
Invest Smarter with A.I. PowerStart My Trial

CorMedix (CRMD) Financials

CorMedix logo
$10.61 +0.07 (+0.66%)
Closing price 04:00 PM Eastern
Extended Trading
$10.60 -0.01 (-0.09%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for CorMedix

Annual Income Statements for CorMedix

This table shows CorMedix's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -21 -18 -25 -33 -27 -44 -22 -28 -30 -46 -18
Consolidated Net Income / (Loss)		 -20 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18
Net Income / (Loss) Continuing Operations		 -20 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18
Total Pre-Tax Income 		-20 -18 -25 -33 -27 -21 -27 -29 -30 -46 -19
Total Operating Income		 -8.90 -17 -25 -33 -27 -21 -27 -29 -31 -49 -22
Total Gross Profit		 -0.26 -0.11 -0.14 0.21 0.03 -0.09 0.03 0.04 0.06 0.00 40
Total Revenue		 0.19 0.21 0.22 0.33 0.43 0.28 0.24 0.19 0.07 0.00 43
Operating Revenue		 0.19 0.21 0.22 0.33 0.43 0.28 0.24 0.19 0.07 0.00 43
Total Cost of Revenue		 -0.45 -0.32 0.37 0.11 0.40 0.37 0.20 0.15 0.00 0.00 3.19
Operating Cost of Revenue		 0.45 0.32 0.37 0.11 0.40 0.37 0.20 0.15 0.00 0.00 3.19
Total Operating Expenses		 8.65 17 25 33 27 21 27 29 31 49 63
Selling, General & Admin Expense		 7.33 10 8.88 8.65 8.07 9.87 14 16 20 18 30
Marketing Expense		 - - - - - - - - - 18 29
Research & Development Expense		 1.32 6.28 16 24 19 11 13 13 11 13 3.94
Total Other Income / (Expense), net		 -12 -1.53 0.12 -0.17 0.03 -0.49 0.11 -0.02 0.34 2.62 3.03
Interest Expense		 2.46 0.00 0.00 0.01 0.00 0.79 0.03 0.02 0.03 0.03 0.04
Interest & Investment Income		 -0.09 0.06 0.13 0.11 0.03 0.32 0.12 0.01 0.33 2.68 2.58
Other Income / (Expense), net		 -9.00 -1.59 -0.01 -0.28 -0.00 -0.02 0.02 -0.02 0.04 -0.03 0.49
Income Tax Expense		 - - - - 0.00 -5.06 -5.17 -1.25 -0.59 0.00 -1.39
Basic Earnings per Share		 ($0.96) ($0.58) ($0.65) ($0.60) ($1.51) ($1.80) ($0.77) ($0.75) ($0.74) ($0.91) ($0.30)
Weighted Average Basic Shares Outstanding		 21.44M 31.34M 37.97M 55.14M 17.82M 24.15M 28.56M 37.67M 40.27M 50.90M 58.87M
Diluted Earnings per Share		 ($0.96) ($0.58) ($0.65) ($0.60) ($1.51) ($1.80) ($0.77) - - ($0.91) ($0.30)
Weighted Average Diluted Shares Outstanding		 21.44M 31.34M 37.97M 55.14M 17.82M 24.15M 28.56M 37.67M 44.50M 50.90M 58.87M

Quarterly Income Statements for CorMedix

This table shows CorMedix's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -6.85 -8.21 -11 -11 -9.75 -15 -14 -14 -2.77 13 21
Consolidated Net Income / (Loss)		 -6.85 -8.21 -11 -11 -9.74 -15 -14 -14 -2.78 13 21
Net Income / (Loss) Continuing Operations		 -6.85 -8.21 -11 -11 -9.74 -15 -14 -14 -2.78 13 21
Total Pre-Tax Income 		-6.85 -8.21 -11 -11 -9.74 -15 -16 -14 -2.78 13 21
Total Operating Income		 -6.96 -8.39 -11 -12 -10 -16 -17 -15 -3.29 13 20
Total Gross Profit		 0.01 0.03 0.00 0.00 0.00 - -0.82 0.30 11 30 37
Total Revenue		 0.01 0.03 0.00 0.00 0.00 - 0.00 1.31 11 31 39
Operating Revenue		 0.01 0.03 0.00 0.00 0.00 - 0.00 1.31 11 31 39
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 - 0.82 0.51 0.69 1.18 1.60
Operating Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 - 0.82 0.51 0.69 1.18 1.60
Total Operating Expenses		 6.97 8.42 11 12 10 16 16 16 14 17 17
Selling, General & Admin Expense		 4.63 5.58 7.61 3.75 3.74 2.58 8.71 7.56 6.58 0.77 9.69
Marketing Expense		 - - - 3.26 4.06 - 6.34 7.39 6.75 - 4.47
Research & Development Expense		 2.34 2.84 3.41 4.79 2.66 2.29 0.84 0.65 0.73 1.73 3.19
Total Other Income / (Expense), net		 0.11 0.13 0.45 0.53 0.72 0.91 0.84 0.65 0.51 1.03 0.52
Interest Expense		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Interest & Investment Income		 0.09 0.18 0.45 0.55 0.77 0.92 0.86 0.66 0.55 0.51 0.57
Other Income / (Expense), net		 0.02 -0.04 0.01 -0.01 -0.03 0.00 -0.00 -0.00 -0.03 0.53 -0.04
Income Tax Expense		 0.00 - 0.00 0.00 0.00 - -1.39 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.17) ($0.20) ($0.24) ($0.25) ($0.17) ($0.25) ($0.25) ($0.25) ($0.05) $0.25 $0.32
Weighted Average Basic Shares Outstanding		 41.18M 40.27M 44.09M 45.37M 56.55M 50.90M 57.50M 57.62M 58.83M 58.87M 65.24M
Diluted Earnings per Share		 - - - - ($0.17) - ($0.25) - ($0.05) - $0.30
Weighted Average Diluted Shares Outstanding		 41.28M 44.50M 45.38M 54.81M 56.55M 50.90M 57.50M 55.86M 58.83M 58.87M 68.98M
Weighted Average Basic & Diluted Shares Outstanding		 41.28M 44.50M 45.38M 54.81M 54.81M 54.98M 54.96M 55.86M 60.68M 0.00 67.82M

Annual Cash Flow Statements for CorMedix

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 1.97 7.48 -3.75 2.32 7.24 -1.27 26 11 -10 0.45 -3.07
Net Cash From Operating Activities		 -6.32 -13 -22 -29 -24 -15 -22 -21 -24 -38 -51
Net Cash From Continuing Operating Activities		 -6.32 -13 -22 -29 -24 -15 -22 -21 -24 -38 -51
Net Income / (Loss) Continuing Operations		 -20 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18
Consolidated Net Income / (Loss)		 -20 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18
Depreciation Expense		 0.02 0.02 0.03 0.04 0.07 0.07 0.13 0.06 0.08 0.07 0.15
Amortization Expense		 - - - 0.00 0.00 0.31 0.03 0.12 0.12 0.13 0.30
Non-Cash Adjustments To Reconcile Net Income		 15 5.64 2.59 1.51 1.11 2.54 0.66 5.05 4.07 5.49 6.13
Changes in Operating Assets and Liabilities, net		 -0.52 0.01 -0.23 2.88 1.94 -1.54 -0.76 1.84 1.07 2.23 -39
Net Cash From Investing Activities		 -0.03 -24 11 10 1.56 -12 7.43 -9.13 -3.71 -17 21
Net Cash From Continuing Investing Activities		 -0.03 -24 11 10 1.56 -12 7.43 -9.13 -3.71 -17 21
Purchase of Property, Plant & Equipment		 -0.03 -0.02 -0.06 -0.15 -0.05 -0.04 -0.11 -1.43 -0.22 -0.33 -0.12
Purchase of Investments		 0.00 -24 0.00 -13 0.00 -14 -8.55 - -31 -77 -27
Sale and/or Maturity of Investments		 - - 11 24 1.60 2.12 16 -7.71 28 60 48
Net Cash From Financing Activities		 8.36 44 7.09 21 29 26 40 42 18 56 26
Net Cash From Continuing Financing Activities		 8.36 44 7.09 21 30 26 40 42 18 56 26
Issuance of Common Equity		 6.72 28 6.23 19 22 15 40 41 18 56 19
Other Financing Activities, net		 0.32 15 0.86 0.01 0.04 8.80 0.41 0.30 0.13 0.09 7.44
Effect of Exchange Rate Changes		 -0.05 -0.02 0.00 0.02 -0.01 -0.00 0.01 -0.01 -0.01 0.00 -0.00
Cash Interest Paid		 0.00 0.00 0.00 0.01 0.00 0.01 0.03 0.02 0.03 0.03 0.04

Quarterly Cash Flow Statements for CorMedix

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -5.68 -0.10 -18 -5.61 34 -9.68 -8.46 -6.71 6.75 5.36 26
Net Cash From Operating Activities		 -6.00 -6.15 -10 -8.57 -8.70 -11 -17 -14 -14 -5.61 20
Net Cash From Continuing Operating Activities		 -6.05 -6.15 -10 -8.57 -8.70 -11 -17 -14 -14 -5.75 20
Net Income / (Loss) Continuing Operations		 -6.85 -8.21 -11 -11 -9.74 -15 -14 -14 -2.78 13 21
Consolidated Net Income / (Loss)		 -6.85 -8.21 -11 -11 -9.74 -15 -14 -14 -2.78 13 21
Depreciation Expense		 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.08 0.11
Amortization Expense		 0.03 0.03 0.03 0.03 0.03 0.03 0.04 0.09 0.09 0.09 0.09
Non-Cash Adjustments To Reconcile Net Income		 1.35 0.87 2.22 1.06 1.00 1.22 2.44 1.26 1.23 1.19 3.50
Changes in Operating Assets and Liabilities, net		 -0.60 1.13 -2.09 1.59 -0.01 2.74 -5.35 -1.27 -12 -21 -4.62
Net Cash From Investing Activities		 -0.11 -0.00 -15 -2.39 -0.59 0.60 8.94 6.27 6.32 -0.30 -0.19
Net Cash From Continuing Investing Activities		 -0.11 -0.00 -15 -2.39 -0.59 0.60 8.94 6.27 6.32 -0.30 -0.19
Purchase of Property, Plant & Equipment		 -0.08 -0.13 -0.01 -0.01 -0.01 -0.30 -0.06 -0.03 -0.01 -0.01 -0.01
Purchase of Investments		 -8.09 -8.77 -25 -17 -18 -16 -7.69 -12 -1.67 -5.29 -9.98
Sale and/or Maturity of Investments		 8.05 8.90 11 15 18 17 17 18 8.00 5.00 9.80
Net Cash From Financing Activities		 0.44 6.05 7.20 5.35 43 0.47 -0.10 1.06 14 11 6.09
Net Cash From Continuing Financing Activities		 0.44 6.05 7.20 5.35 43 0.47 -0.10 1.06 14 11 6.09
Issuance of Common Equity		 0.31 6.05 - - 43 0.43 0.00 - 12 5.51 6.76
Other Financing Activities, net		 0.13 - 7.20 -7.16 0.02 0.03 -0.10 0.05 1.71 5.78 -0.67
Effect of Exchange Rate Changes		 -0.01 0.02 0.00 0.00 -0.00 0.00 -0.00 -0.00 0.00 -0.00 0.00
Cash Interest Paid		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01

Annual Balance Sheets for CorMedix

This table presents CorMedix's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 5.10 37 22 13 19 29 49 69 62 82 119
Total Current Assets		 5.04 37 22 13 19 29 48 66 60 79 115
Cash & Equivalents		 4.34 12 8.06 10 18 16 42 53 43 44 41
Short-Term Investments		 0.00 24 12 1.60 0.00 12 4.44 12 16 32 11
Accounts Receivable		 0.08 0.32 0.01 0.06 0.01 0.00 0.00 0.05 - 0.00 52
Inventories, net		 0.46 0.38 0.17 0.59 0.43 0.34 0.14 0.00 0.00 2.11 7.60
Prepaid Expenses		 0.16 0.81 1.32 0.45 0.43 0.48 1.47 0.82 0.63 1.24 3.63
Plant, Property, & Equipment, net		 0.04 0.04 0.07 0.19 0.16 0.12 0.11 1.47 1.61 1.87 1.83
Total Noncurrent Assets		 0.02 0.01 0.01 0.00 0.00 0.00 1.01 1.00 0.88 0.74 2.44
Long-Term Investments		 - - - - - - - 0.10 0.10 0.10 0.11
Intangible Assets		 - - - - - - - - - 0.00 1.84
Other Noncurrent Operating Assets		 0.02 0.01 0.01 - 0.00 0.00 1.01 0.90 0.78 0.64 0.49
Total Liabilities & Shareholders' Equity		 5.10 37 22 13 19 29 49 69 62 82 119
Total Liabilities		 1.46 3.09 4.09 6.26 14 5.83 5.09 6.15 6.98 12 34
Total Current Liabilities		 1.43 3.06 4.09 6.26 7.77 5.83 4.16 5.35 6.31 11 34
Accounts Payable		 0.89 1.71 1.65 1.81 2.59 1.02 1.13 2.21 2.20 4.28 1.72
Accrued Expenses		 0.52 1.22 2.34 4.36 5.17 4.80 2.92 3.01 3.97 6.97 32
Other Current Liabilities		 - - - - - 0.00 0.11 0.12 0.13 0.15 0.17
Total Noncurrent Liabilities		 0.04 0.03 0.00 0.00 6.13 0.00 0.92 0.80 0.67 0.52 0.35
Other Noncurrent Operating Liabilities		 - - - - 0.00 0.00 0.92 0.80 0.67 0.52 0.35
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3.63 34 18 7.19 4.93 24 44 63 55 70 85
Total Preferred & Common Equity		 3.63 34 18 7.19 4.93 24 44 63 55 70 85
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3.63 34 18 7.19 4.93 24 44 63 55 70 85
Common Stock		 80 128 137 159 184 219 262 308 330 392 424
Retained Earnings		 -76 -94 -119 -152 -179 -195 -217 -246 -275 -322 -340
Accumulated Other Comprehensive Income / (Loss)		 0.10 0.06 0.08 0.10 0.10 0.10 0.10 0.09 0.08 0.09 0.09

Quarterly Balance Sheets for CorMedix

This table presents CorMedix's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 68 62 59 57 91 68 58 78 150
Total Current Assets		 65 60 57 55 89 63 53 73 145
Cash & Equivalents		 49 43 25 20 53 35 29 35 66
Short-Term Investments		 16 16 30 33 33 23 17 11 11
Accounts Receivable		 0.00 0.00 - - - - 0.21 17 55
Inventories, net		 0.00 0.00 - - - 2.32 4.01 6.65 7.49
Prepaid Expenses		 0.61 0.55 1.05 2.14 2.39 2.46 3.37 3.09 5.26
Plant, Property, & Equipment, net		 1.45 1.50 1.61 1.60 1.59 1.91 1.92 1.90 1.73
Total Noncurrent Assets		 0.94 0.91 0.84 0.81 0.78 2.71 2.62 2.53 2.99
Long-Term Investments		 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.11 0.11
Intangible Assets		 - - - - - 2.00 1.95 1.90 1.79
Other Noncurrent Operating Assets		 0.84 0.81 0.74 0.71 0.68 0.60 0.57 0.53 1.10
Total Liabilities & Shareholders' Equity		 68 62 59 57 91 68 58 78 150
Total Liabilities		 6.01 5.76 5.31 7.98 8.23 10 12 19 35
Total Current Liabilities		 5.27 5.06 4.67 7.39 7.67 9.53 11 18 34
Accounts Payable		 2.50 1.77 1.45 2.90 2.39 2.83 3.34 1.34 1.93
Accrued Expenses		 2.65 3.16 3.09 4.34 5.14 6.55 7.61 17 32
Other Current Liabilities		 0.13 0.13 0.14 0.14 0.15 0.15 0.16 0.16 0.17
Total Noncurrent Liabilities		 0.74 0.70 0.63 0.59 0.56 0.48 0.44 0.39 0.30
Other Noncurrent Operating Liabilities		 - - 0.63 - - - 0.44 0.39 0.30
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 62 56 54 49 83 58 46 59 115
Total Preferred & Common Equity		 62 56 54 49 83 58 46 59 115
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 62 56 54 49 83 58 46 59 115
Common Stock		 322 323 340 346 390 394 396 412 434
Retained Earnings		 -260 -267 -286 -297 -307 -336 -350 -353 -319
Accumulated Other Comprehensive Income / (Loss)		 0.04 0.05 0.10 0.09 0.08 0.08 0.09 0.09 0.08

Annual Metrics And Ratios for CorMedix

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 9,358.97% 11.02% 6.65% 46.95% 30.51% -34.09% -15.55% -20.19% -65.74% -100.00% 0.00%
EBITDA Growth		 -354.32% -1.91% -35.74% -34.03% 19.22% 22.95% -30.97% -8.31% -3.74% -60.58% 56.11%
EBIT Growth		 -239.09% -1.91% -35.77% -34.04% 19.09% 21.72% -29.33% -8.32% -3.83% -60.16% 55.36%
NOPAT Growth		 -81.11% -87.08% -48.68% -32.97% 18.41% 21.80% -29.57% -8.14% -4.03% -59.87% 54.34%
Net Income Growth		 -123.95% 11.08% -35.50% -33.95% 18.72% 38.75% -34.04% -28.07% -5.29% -56.02% 61.31%
EPS Growth		 -39.13% 39.58% -12.07% -33.95% 18.72% -19.21% 57.22% 0.00% 0.00% 0.00% 67.03%
Operating Cash Flow Growth		 -74.68% -98.18% -77.74% -28.39% 17.09% 36.49% -45.94% 3.70% -15.13% -57.70% -31.78%
Free Cash Flow Firm Growth		 -706.03% 10.77% -51.21% -25.99% 17.35% 2.66% -30.29% 7.30% -1.79% -57.81% -69.72%
Invested Capital Growth		 89.31% -119.25% -63.17% -96.72% -35.74% 27.80% 52.34% -25.21% -36.42% -53.29% 641.51%
Revenue Q/Q Growth		 77.93% -12.07% 41.43% -8.14% -13.31% -0.61% 0.00% 0.00% -28.98% -100.00% 240.63%
EBITDA Q/Q Growth		 -1.52% -10.00% -12.26% -13.10% 31.67% -57.50% -2.01% -6.27% -2.16% -17.41% 57.74%
EBIT Q/Q Growth		 -1.52% -9.99% -12.27% -13.09% 31.60% -55.84% -2.38% -6.44% -2.16% -17.33% 57.12%
NOPAT Q/Q Growth		 -7.88% -11.21% -11.98% -12.77% 31.60% -55.69% -2.67% -6.11% -2.03% -17.47% 56.13%
Net Income Q/Q Growth		 5.63% -9.99% -12.03% -13.00% 31.71% -82.99% -3.68% -6.43% -1.43% -16.45% 61.15%
EPS Q/Q Growth		 30.43% -87.10% -14.04% -13.00% 31.71% -19.21% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -11.48% -19.69% -14.76% -2.80% 0.32% 18.05% -10.29% 0.30% -1.19% -13.57% 9.20%
Free Cash Flow Firm Q/Q Growth		 -43.69% -17.66% -16.30% 1.77% -22.69% 23.45% -9.60% -3.14% 5.51% -13.40% -6.47%
Invested Capital Q/Q Growth		 -105.92% 5.25% 17.18% -98.16% 58.20% -24.64% 15.81% -5.16% -79.85% -101.22% 161.29%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -135.53% -51.68% -63.62% 65.09% 7.68% -31.76% 14.37% 22.00% 94.29% 0.00% 92.66%
EBITDA Margin		 -9,450.22% -8,675.05% -11,041.03% -10,070.21% -6,233.21% -7,287.37% -11,300.69% -15,335.95% -46,443.53% 0.00% -49.25%
Operating Margin		 -4,703.30% -7,925.56% -11,048.80% -9,997.39% -6,250.44% -7,416.31% -11,378.44% -15,417.51% -46,819.91% 0.00% -51.43%
EBIT Margin		 -9,458.18% -8,682.22% -11,052.45% -10,081.41% -6,250.48% -7,423.78% -11,368.54% -15,428.66% -46,763.12% 0.00% -50.30%
Profit (Net Income) Margin		 -10,806.25% -8,655.37% -10,996.46% -10,023.45% -6,242.40% -5,801.29% -9,207.70% -14,774.70% -45,409.90% 0.00% -41.24%
Tax Burden Percent		 104.56% 103.63% 100.00% 99.74% 100.00% 76.45% 80.99% 95.76% 98.07% 100.00% 92.78%
Interest Burden Percent		 109.27% 96.20% 99.49% 99.68% 99.87% 102.21% 100.00% 100.01% 99.02% 94.60% 88.37%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -116.81%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -113.25%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 93.64%
Return on Equity (ROE)		 10,546.51% -96.62% -95.10% -264.00% -442.46% -114.99% -64.91% -52.72% -50.40% -74.02% -23.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -166.09%
Operating Return on Assets (OROA)		 -443.91% -86.47% -83.95% -187.79% -166.45% -87.07% -69.04% -49.82% -46.70% 0.00% -21.77%
Return on Assets (ROA)		 -507.18% -86.20% -83.53% -186.71% -166.23% -68.04% -55.92% -47.71% -45.35% 0.00% -17.85%
Return on Common Equity (ROCE)		 10,595.64% -96.62% -95.10% -263.99% -442.42% -114.99% -64.91% -52.72% -50.40% -74.02% -23.17%
Return on Equity Simple (ROE_SIMPLE)		 -562.76% -53.47% -138.33% -458.89% -543.74% -69.50% -49.81% -44.92% -53.94% -66.06% -21.18%
Net Operating Profit after Tax (NOPAT)		 -6.23 -12 -17 -23 -19 -15 -19 -21 -21 -34 -16
NOPAT Margin		 -3,292.31% -5,547.89% -7,734.16% -6,998.17% -4,375.31% -5,191.41% -7,964.91% -10,792.26% -32,773.94% 0.00% -36.00%
Net Nonoperating Expense Percent (NNEP)		 -411.46% -32.73% -26.16% -61.33% -67.36% -8.60% -7.92% -13.55% -13.25% -17.85% -3.56%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -48.86% -18.49%
Cost of Revenue to Revenue		 -235.53% -151.68% 163.62% 34.91% 92.32% 131.76% 85.63% 78.00% 5.71% 0.00% 7.34%
SG&A Expenses to Revenue		 3,871.03% 4,884.39% 3,963.79% 2,627.28% 1,878.73% 3,482.59% 5,801.06% 8,561.30% 30,586.61% 0.00% 68.92%
R&D to Revenue		 696.73% 2,989.49% 7,021.40% 7,435.20% 4,379.39% 3,901.95% 5,591.75% 6,878.21% 16,327.59% 0.00% 9.07%
Operating Expenses to Revenue		 4,567.77% 7,873.88% 10,985.19% 10,062.48% 6,258.12% 7,384.55% 11,392.81% 15,439.51% 46,914.20% 0.00% 144.09%
Earnings before Interest and Taxes (EBIT)		 -18 -18 -25 -33 -27 -21 -27 -29 -31 -49 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -18 -25 -33 -27 -21 -27 -29 -30 -49 -21
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 11.27 1.87 3.26 19.24 23.29 7.44 4.80 2.73 3.41 2.73 5.63
Price to Tangible Book Value (P/TBV)		 11.27 1.87 3.26 19.24 23.29 7.44 4.80 2.73 3.41 2.73 5.76
Price to Revenue (P/Rev)		 216.37 302.80 259.21 420.26 267.38 620.71 887.07 897.58 2,871.04 0.00 10.97
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.93
Enterprise Value to Revenue (EV/Rev)		 193.45 133.59 168.46 383.36 240.22 520.07 692.53 553.49 1,968.73 0.00 9.78
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 1.24 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 1.24 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 17.82 -1.06 -1.08 -1.30 -1.96 -1.41 -1.11 -1.05 -1.06 -1.08 -0.83
Leverage Ratio		 -20.79 1.12 1.14 1.41 2.66 1.69 1.16 1.11 1.11 1.15 1.30
Compound Leverage Factor		 -22.72 1.08 1.13 1.41 2.66 1.73 1.16 1.11 1.10 1.09 1.15
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 55.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 55.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.03% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.97% 100.00% 100.00% 99.99% 44.61% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.23 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.44 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.23 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.33 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.62 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.33 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -14.84 8.27 -1.85 -10.06 -12.34 7.43 18.12 11.40 9.34 3.17 4.94
Noncontrolling Interest Sharing Ratio		 -0.47% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.53 12.11 5.34 2.12 2.40 5.04 11.58 12.44 9.44 6.97 3.39
Quick Ratio		 3.10 11.66 4.93 1.92 2.27 4.86 11.14 12.26 9.32 6.67 3.05
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 -11 -16 -21 -17 -17 -22 -20 -20 -32 -55
Operating Cash Flow to CapEx		 -24,883.15% -81,101.24% -37,915.97% -18,808.84% -48,474.35% -41,158.36% -19,502.87% -1,484.23% -11,103.54% -11,735.25% -43,735.12%
Free Cash Flow to Firm to Interest Expense		 -4.92 -2,728.80 -12,476.03 -3,667.41 -9,093.13 -21.05 -650.09 -1,255.85 -768.62 -937.74 -1,499.31
Operating Cash Flow to Interest Expense		 -2.56 -3,160.17 -16,983.52 -5,087.59 -12,653.80 -19.11 -661.16 -1,326.93 -918.60 -1,119.94 -1,390.32
Operating Cash Flow Less CapEx to Interest Expense		 -2.57 -3,164.06 -17,028.31 -5,114.64 -12,679.90 -19.16 -664.55 -1,416.33 -926.88 -1,129.48 -1,393.50
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.05 0.01 0.01 0.02 0.03 0.01 0.01 0.00 0.00 0.00 0.43
Accounts Receivable Turnover		 4.59 1.06 1.37 8.65 11.45 51.79 141.06 7.84 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 1.35 0.30 0.78 0.97 0.85 2.03 0.00 0.00 0.66
Fixed Asset Turnover		 4.88 5.30 4.17 2.57 2.48 2.00 2.05 0.24 0.04 0.00 23.54
Accounts Payable Turnover		 0.00 0.00 0.22 0.07 0.18 0.21 0.19 0.09 0.00 0.00 1.06
Days Sales Outstanding (DSO)		 79.57 343.89 266.93 42.21 31.87 7.05 2.59 46.57 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 270.41 1,207.94 470.39 375.03 429.45 179.60 0.00 0.00 555.18
Days Payable Outstanding (DPO)		 0.00 0.00 1,669.69 5,482.44 2,022.51 1,766.77 1,917.59 4,089.77 215,622.77 0.00 343.19
Cash Conversion Cycle (CCC)		 79.57 343.89 -1,132.35 -4,232.30 -1,520.25 -1,384.69 -1,485.55 -3,863.60 -215,622.77 0.00 211.99
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.71 -1.55 -2.52 -4.96 -6.74 -4.86 -2.32 -2.90 -3.96 -6.07 33
Invested Capital Turnover		 -0.05 -0.19 -0.11 -0.09 -0.07 -0.05 -0.07 -0.07 -0.02 0.00 3.24
Increase / (Decrease) in Invested Capital		 5.89 -0.84 -0.98 -2.44 -1.77 1.87 2.55 -0.58 -1.06 -2.11 39
Enterprise Value (EV)		 37 28 38 126 103 147 166 106 129 115 425
Market Capitalization		 41 64 58 138 115 176 212 171 188 191 477
Book Value per Share		 $0.16 $0.96 $0.44 $0.11 $0.05 $0.92 $1.38 $1.65 $1.33 $1.28 $1.44
Tangible Book Value per Share		 $0.16 $0.96 $0.44 $0.11 $0.05 $0.92 $1.38 $1.65 $1.33 $1.28 $1.41
Total Capital		 3.63 34 18 7.19 11 24 44 63 55 70 85
Total Debt		 0.00 0.00 0.00 0.00 6.13 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 6.13 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.34 -36 -20 -12 -12 -29 -47 -66 -59 -76 -52
Capital Expenditures (CapEx)		 0.03 0.02 0.06 0.15 0.05 0.04 0.11 1.43 0.22 0.33 0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.73 -1.56 -2.60 -5.15 -6.90 -4.99 -2.52 -4.47 -5.68 -8.06 29
Debt-free Net Working Capital (DFNWC)		 3.61 34 18 7.01 11 24 44 61 53 68 81
Net Working Capital (NWC)		 3.61 34 18 7.01 11 24 44 61 53 68 81
Net Nonoperating Expense (NNE)		 14 6.53 7.31 9.96 8.02 1.73 2.97 7.60 8.26 12 2.28
Net Nonoperating Obligations (NNO)		 -4.34 -36 -20 -12 -12 -29 -47 -66 -59 -76 -52
Total Depreciation and Amortization (D&A)		 0.02 0.02 0.03 0.04 0.07 0.39 0.16 0.18 0.21 0.21 0.46
Debt-free, Cash-free Net Working Capital to Revenue		 -384.08% -742.33% -1,158.89% -1,563.31% -1,604.59% -1,760.62% -1,053.49% -2,343.31% -8,678.15% 0.00% 66.82%
Debt-free Net Working Capital to Revenue		 1,908.65% 16,179.27% 7,915.86% 2,127.69% 2,535.81% 8,303.90% 18,400.87% 32,012.69% 81,397.21% 0.00% 185.72%
Net Working Capital to Revenue		 1,908.65% 16,179.27% 7,915.86% 2,127.69% 2,535.81% 8,303.90% 18,400.87% 32,012.69% 81,397.21% 0.00% 185.72%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($4.80) ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) ($0.74) ($0.91) ($0.30)
Adjusted Weighted Average Basic Shares Outstanding		 4.82M 7.22M 8.14M 16.30M 119.01M 26.13M 38.02M 38.73M 40.27M 50.90M 58.87M
Adjusted Diluted Earnings per Share		 ($4.80) ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) $0.00 $0.00 ($0.30)
Adjusted Weighted Average Diluted Shares Outstanding		 4.82M 7.22M 8.14M 16.30M 119.01M 26.13M 38.02M 38.73M 44.50M 54.98M 58.87M
Adjusted Basic & Diluted Earnings per Share		 ($4.80) ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.29M 6.27M 7.59M 11.03M 89.08M 24.15M 28.56M 37.67M 44.50M 54.98M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -6.23 -12 -17 -23 -19 -15 -19 -21 -21 -34 -16
Normalized NOPAT Margin		 -3,292.31% -5,547.89% -7,734.16% -6,998.17% -4,375.31% -5,191.41% -7,964.91% -10,792.26% -32,773.94% 0.00% -36.00%
Pre Tax Income Margin		 -10,335.19% -8,352.02% -10,996.46% -10,049.50% -6,242.40% -7,587.87% -11,368.54% -15,429.47% -46,305.23% 0.00% -44.45%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -7.26 -4,602.41 -18,893.28 -5,908.67 -14,342.97 -26.70 -818.55 -1,847.76 -1,153.57 -1,428.35 -600.66
NOPAT to Interest Expense		 -2.53 -2,940.91 -13,220.93 -4,101.60 -10,040.01 -18.67 -573.48 -1,292.50 -808.48 -999.26 -429.87
EBIT Less CapEx to Interest Expense		 -7.27 -4,606.31 -18,938.07 -5,935.72 -14,369.07 -26.75 -821.94 -1,937.16 -1,161.84 -1,437.90 -603.84
NOPAT Less CapEx to Interest Expense		 -2.54 -2,944.81 -13,265.73 -4,128.65 -10,066.11 -18.72 -576.87 -1,381.90 -816.75 -1,008.80 -433.05
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -1.38% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for CorMedix

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -82.10% -47.33% -100.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 19.23% -8.29% -56.69% -44.91% -51.68% -86.34% -51.99% -29.08% 69.31% 187.33% 221.84%
EBIT Growth		 19.05% -8.30% -56.26% -44.61% -51.28% -85.77% -51.83% -29.48% 68.36% 185.94% 220.22%
NOPAT Growth		 18.72% -7.83% -56.66% -43.25% -50.35% -86.77% -51.62% -29.62% 68.59% 217.94% 272.11%
Net Income Growth		 20.02% -5.36% -50.23% -48.24% -42.18% -79.73% -36.90% -25.53% 71.50% 191.26% 242.71%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 70.59% 0.00% 220.00%
Operating Cash Flow Growth		 -8.94% -4.86% -54.11% -56.94% -45.07% -74.59% -66.54% -63.78% -56.94% 47.75% 214.02%
Free Cash Flow Firm Growth		 9.30% 0.95% -160.70% -56.32% -19.89% -83.95% -72.13% -83.70% -174.78% -193.47% -30.28%
Invested Capital Growth		 20.23% -36.42% 2.34% -24.23% -37.01% -53.29% 87.29% 115.93% 517.02% 641.51% 15,531.26%
Revenue Q/Q Growth		 -67.92% 335.70% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 777.11% 168.07% 27.26%
EBITDA Q/Q Growth		 15.20% -21.69% -30.74% -7.41% 11.24% -49.49% -6.64% 8.78% 78.89% 525.33% 48.78%
EBIT Q/Q Growth		 15.10% -21.55% -30.49% -7.39% 11.18% -49.26% -6.64% 8.41% 78.30% 505.46% 49.19%
NOPAT Q/Q Growth		 15.52% -20.50% -31.33% -7.15% 11.33% -49.69% -6.61% 8.40% 78.52% 662.16% 55.58%
Net Income Q/Q Growth		 9.88% -19.77% -28.73% -6.68% 13.57% -51.41% 1.95% 2.18% 80.38% 584.89% 53.32%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -9.76% -2.66% -68.87% 17.52% -1.46% -23.55% -61.09% 18.89% 2.78% 58.87% 451.53%
Free Cash Flow Firm Q/Q Growth		 -10.43% 11.34% -61.09% 0.89% 15.30% -36.02% -50.74% -5.78% -26.69% -45.28% 33.08%
Invested Capital Q/Q Growth		 7.13% -79.85% 51.97% -54.87% -2.42% -101.22% 96.02% 294.22% 2,580.55% 161.29% 13.44%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 78.45% 98.63% 0.00% 0.00% 0.00% 0.00% 0.00% 22.68% 94.01% 97.80% 95.91%
EBITDA Margin		 -101,010.75% -28,211.21% 0.00% 0.00% 0.00% 0.00% 0.00% -1,162.91% -27.98% 44.40% 51.91%
Operating Margin		 -102,126.07% -28,244.66% 0.00% 0.00% 0.00% 0.00% 0.00% -1,171.47% -28.70% 42.12% 51.50%
EBIT Margin		 -101,780.28% -28,394.28% 0.00% 0.00% 0.00% 0.00% 0.00% -1,171.59% -28.99% 43.84% 51.40%
Profit (Net Income) Margin		 -100,538.67% -27,637.70% 0.00% 0.00% 0.00% 0.00% 0.00% -1,083.48% -24.24% 43.84% 52.82%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 91.21% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.78% 97.34% 96.02% 95.39% 92.83% 94.17% 94.93% 92.48% 83.62% 100.00% 102.77%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -53.62% 136.68% 229.55%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -52.90% 135.86% 228.79%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 49.34% -112.34% -179.78%
Return on Equity (ROE)		 -46.61% -50.40% -58.41% -66.62% -57.05% -74.02% -89.76% -111.55% -4.28% 24.34% 49.77%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,401.45% -407.60% -166.09% -61.83%
Operating Return on Assets (OROA)		 -136.39% -28.36% 0.00% 0.00% 0.00% 0.00% 0.00% -26.67% -4.38% 18.97% 39.00%
Return on Assets (ROA)		 -134.72% -27.60% 0.00% 0.00% 0.00% 0.00% 0.00% -24.66% -3.66% 18.97% 40.08%
Return on Common Equity (ROCE)		 -46.61% -50.40% -58.41% -66.62% -57.05% -74.02% -89.76% -111.55% -4.28% 24.34% 49.77%
Return on Equity Simple (ROE_SIMPLE)		 -52.00% 0.00% -61.63% -75.23% -47.83% 0.00% -86.60% -115.01% -78.60% 0.00% 14.95%
Net Operating Profit after Tax (NOPAT)		 -4.87 -5.87 -7.71 -8.26 -7.33 -11 -12 -11 -2.30 13 20
NOPAT Margin		 -71,488.25% -19,771.26% 0.00% 0.00% 0.00% 0.00% 0.00% -820.03% -20.09% 42.12% 51.50%
Net Nonoperating Expense Percent (NNEP)		 -3.03% -3.75% -4.85% -5.19% -3.34% -5.60% -4.86% -7.04% -0.72% 0.83% 0.76%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -15.64% - - - 15.28% 17.52%
Cost of Revenue to Revenue		 21.55% 1.37% 0.00% 0.00% 0.00% 0.00% 0.00% 39.03% 5.99% 3.83% 4.09%
SG&A Expenses to Revenue		 67,889.31% 18,770.79% 0.00% 0.00% 0.00% 0.00% 0.00% 578.76% 57.44% 2.51% 24.80%
R&D to Revenue		 34,315.21% 9,572.50% 0.00% 0.00% 0.00% 0.00% 0.00% 49.84% 6.35% 5.62% 8.17%
Operating Expenses to Revenue		 102,204.52% 28,343.29% 0.00% 0.00% 0.00% 0.00% 0.00% 1,194.16% 122.70% 55.68% 44.42%
Earnings before Interest and Taxes (EBIT)		 -6.94 -8.43 -11 -12 -10 -16 -17 -15 -3.32 13 20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.89 -8.38 -11 -12 -10 -16 -17 -15 -3.21 14 20
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.07 3.41 3.48 4.43 2.51 2.73 4.02 5.24 8.10 5.63 3.70
Price to Tangible Book Value (P/TBV)		 2.07 3.41 3.48 4.43 2.51 2.73 4.16 5.47 8.37 5.76 3.76
Price to Revenue (P/Rev)		 1,268.47 2,871.04 3,251.82 5,950.42 7,044.87 0.00 0.00 185.19 37.24 10.97 5.15
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 24.73
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.04%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 418.06 34.12 12.93 9.32
Enterprise Value to Revenue (EV/Rev)		 633.16 1,968.73 2,285.45 4,526.62 4,142.11 0.00 0.00 150.18 33.63 9.78 4.21
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 22.36
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.26
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.99
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.01 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.06 -1.03 -1.05 -1.04 -1.08 -1.02 -1.03 -0.93 -0.83 -0.79
Leverage Ratio		 1.09 1.11 1.09 1.13 1.10 1.15 1.14 1.21 1.19 1.30 1.26
Compound Leverage Factor		 1.08 1.08 1.05 1.07 1.02 1.08 1.08 1.11 1.00 1.30 1.29
Debt to Total Capital		 1.23% 0.00% 0.00% 1.20% 0.66% 0.00% 0.81% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.23% 0.00% 0.00% 1.20% 0.66% 0.00% 0.81% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.77% 100.00% 100.00% 98.80% 99.34% 100.00% 99.18% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.02 0.00 0.00 -0.02 -0.01 0.00 -0.01 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 1.97 0.00 0.00 1.37 2.08 0.00 1.07 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.02 0.00 0.00 -0.02 -0.01 0.00 -0.01 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.03 0.00 0.00 -0.02 -0.02 0.00 -0.01 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 2.79 0.00 0.00 1.95 2.96 0.00 1.52 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.03 0.00 0.00 -0.02 -0.02 0.00 -0.01 0.00 0.00 0.00 0.00
Altman Z-Score		 6.82 10.51 14.93 9.35 11.25 4.51 7.19 4.10 9.61 5.92 6.24
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.79 9.44 12.15 7.39 11.61 6.97 6.65 4.79 3.96 3.39 4.21
Quick Ratio		 11.66 9.32 11.89 7.09 11.29 6.67 6.14 4.12 3.43 3.05 3.84
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.43 -4.82 -7.76 -7.69 -6.51 -8.86 -13 -14 -18 -26 -17
Operating Cash Flow to CapEx		 -7,845.58% -4,780.27% -70,390.67% -134,829.03% -84,894.78% -3,631.15% -28,235.89% -40,357.34% -139,769.68% -56,890.63% 193,932.43%
Free Cash Flow to Firm to Interest Expense		 -618.93 -548.72 -883.95 -1,314.10 -496.63 -1,351.17 -1,357.69 -2,154.45 -1,788.21 -2,597.87 -1,738.42
Operating Cash Flow to Interest Expense		 -683.16 -701.33 -1,184.35 -1,465.12 -663.27 -1,639.06 -1,760.07 -2,141.54 -1,364.04 -561.06 1,972.27
Operating Cash Flow Less CapEx to Interest Expense		 -691.87 -716.00 -1,186.04 -1,466.21 -664.05 -1,684.20 -1,766.30 -2,146.84 -1,365.01 -562.05 1,971.25
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.15 0.43 0.76
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 2.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.66 0.81
Fixed Asset Turnover		 0.06 0.04 0.04 0.02 0.02 0.00 0.00 0.74 7.32 23.54 45.44
Accounts Payable Turnover		 0.04 0.00 0.00 0.00 0.00 0.00 0.38 0.43 1.08 1.06 1.67
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 174.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 555.18 451.02
Days Payable Outstanding (DPO)		 10,218.47 215,622.77 263,507.26 525,271.11 1,867,035.68 0.00 952.68 858.02 337.83 343.19 218.86
Cash Conversion Cycle (CCC)		 -10,043.60 -215,622.77 -263,507.26 -525,271.11 -1,867,035.68 0.00 0.00 -858.02 -337.83 211.99 232.16
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.20 -3.96 -1.90 -2.94 -3.02 -6.07 -0.24 0.47 13 33 37
Invested Capital Turnover		 -0.04 -0.02 -0.03 -0.01 -0.01 0.00 0.00 -1.06 2.67 3.24 4.46
Increase / (Decrease) in Invested Capital		 0.56 -1.06 0.05 -0.57 -0.81 -2.11 1.66 3.41 16 39 38
Enterprise Value (EV)		 58 129 132 165 123 115 175 196 429 425 347
Market Capitalization		 117 188 188 217 209 191 233 242 475 477 425
Book Value per Share		 $1.37 $1.33 $1.21 $1.08 $1.52 $1.28 $1.01 $0.80 $1.00 $1.44 $1.76
Tangible Book Value per Share		 $1.37 $1.33 $1.21 $1.08 $1.52 $1.28 $0.97 $0.77 $0.97 $1.41 $1.73
Total Capital		 57 55 54 50 84 70 58 46 59 85 115
Total Debt		 0.70 0.00 0.00 0.59 0.56 0.00 0.48 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.70 0.00 0.00 0.59 0.56 0.00 0.48 0.00 0.00 0.00 0.00
Net Debt		 -59 -59 -56 -52 -86 -76 -58 -46 -46 -52 -78
Capital Expenditures (CapEx)		 0.08 0.13 0.01 0.01 0.01 0.30 0.06 0.03 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.51 -5.68 -3.62 -5.25 -5.28 -8.06 -4.75 -3.53 8.64 29 33
Debt-free Net Working Capital (DFNWC)		 55 53 52 47 81 68 54 42 55 81 110
Net Working Capital (NWC)		 55 53 52 47 81 68 54 42 55 81 110
Net Nonoperating Expense (NNE)		 1.98 2.34 2.86 3.01 2.42 3.79 2.77 3.44 0.48 -0.53 -0.52
Net Nonoperating Obligations (NNO)		 -59 -59 -56 -52 -86 -76 -58 -46 -46 -52 -78
Total Depreciation and Amortization (D&A)		 0.05 0.05 0.05 0.05 0.05 0.05 0.06 0.11 0.11 0.17 0.20
Debt-free, Cash-free Net Working Capital to Revenue		 -4,898.54% -8,678.15% -6,266.32% -14,377.30% -17,776.99% 0.00% 0.00% -270.06% 67.73% 66.82% 39.94%
Debt-free Net Working Capital to Revenue		 59,284.64% 81,397.21% 90,193.71% 129,350.11% 274,026.98% 0.00% 0.00% 3,221.99% 428.40% 185.72% 133.82%
Net Working Capital to Revenue		 59,284.64% 81,397.21% 90,193.71% 129,350.11% 274,026.98% 0.00% 0.00% 3,221.99% 428.40% 185.72% 133.82%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.17) ($0.20) ($0.24) ($0.25) ($0.17) ($0.25) ($0.25) ($0.25) ($0.05) $0.25 $0.32
Adjusted Weighted Average Basic Shares Outstanding		 41.18M 40.27M 44.09M 45.37M 56.55M 50.90M 57.50M 57.62M 58.83M 58.87M 65.24M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.05) $0.00 $0.30
Adjusted Weighted Average Diluted Shares Outstanding		 41.28M 44.50M 45.38M 54.81M 54.81M 50.90M 54.96M 55.86M 58.83M 58.87M 68.98M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 41.28M 44.50M 45.38M 54.81M 54.81M 54.98M 54.96M 55.86M 60.68M 0.00 67.82M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.87 -5.87 -7.71 -8.26 -7.33 -11 -12 -11 -2.30 9.06 14
Normalized NOPAT Margin		 -71,488.25% -19,771.26% 0.00% 0.00% 0.00% 0.00% 0.00% -820.03% -20.09% 29.49% 36.05%
Pre Tax Income Margin		 -100,538.67% -27,637.70% 0.00% 0.00% 0.00% 0.00% 0.00% -1,083.48% -24.24% 43.84% 52.82%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -790.61 -960.99 -1,253.97 -2,019.82 -800.46 -2,389.80 -1,698.86 -2,334.09 -331.83 1,345.46 2,007.31
NOPAT to Interest Expense		 -555.30 -669.15 -878.76 -1,412.27 -558.77 -1,672.99 -1,188.91 -1,633.71 -229.95 1,292.70 2,011.12
EBIT Less CapEx to Interest Expense		 -799.31 -975.66 -1,255.65 -2,020.90 -801.25 -2,434.94 -1,705.09 -2,339.40 -332.81 1,344.47 2,006.29
NOPAT Less CapEx to Interest Expense		 -564.01 -683.82 -880.45 -1,413.36 -559.55 -1,718.13 -1,195.15 -1,639.01 -230.93 1,291.71 2,010.10
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

CorMedix Inc. (NASDAQ: CRMD) shows significant financial activity and trends over the last four years, with recent quarterly data through Q1 2025 indicating growth as well as ongoing operational challenges.

Positive Trends:

  • In Q1 2025, CorMedix reported a growing operating revenue of approximately $39.1 million, up from $30.7 million in Q4 2024 and significantly higher than earlier quarters in 2024 and 2023.
  • The company achieved a strong gross profit margin in Q1 2025, with gross profit totaling about $37.5 million, reflecting efficient cost management of revenue.
  • Net income has turned positive in Q1 2025, with approximately $20.6 million, an improvement from net losses in all quarters of 2024 and 2023.
  • Diluted earnings per share rose to $0.30 in Q1 2025, compared to negative or low figures in prior quarters, indicating stronger profitability on a per-share basis.
  • Strong cash flow from operating activities in Q1 2025 of approximately $19.7 million suggests good cash generation capabilities, a reversal from negative operating cash flows in prior quarters.
  • Cash and equivalents increased markedly to approximately $66.3 million at the end of Q1 2025, up from about $35.3 million at the end of Q3 2024, improving liquidity.
  • The company raised approximately $6.8 million from issuance of common equity in Q1 2025, augmenting its capital base.

Neutral Factors:

  • Despite improved financials, CorMedix still carries a sizeable accrued expenses balance ($32.3 million as of Q1 2025), reflecting ongoing liabilities to manage.
  • Total operating expenses remained high in Q1 2025 (around $17.4 million), including marketing and R&D expenses, reflecting continued investment in growth opportunities.
  • Interest expense remains low but consistent at about $10,000 per quarter, showing minimal debt servicing costs.

Negative Trends:

  • Prior to Q1 2025, CorMedix experienced consistent net losses across 2023 and most of 2024, with losses exceeding $14 million in some quarters, indicating challenges in profitability before the recent turnaround.
  • Cash flow from operating activities was negative in most quarters prior to Q1 2025, sometimes severely so (e.g., -$17.3 million in Q1 2024), reflecting operational cash burn and potential liquidity pressures.
  • High accrued expenses and liabilities in earlier periods (e.g., $33 million accrued expenses in Q1 2025 and lower equity base) suggest ongoing operational and financial obligations that could pressure cash flow.
  • There is a trend of fluctuating cash flows from investing activities, with large purchases and sales of investments causing significant cash flow volatility quarter to quarter.
  • Although Q1 2025 shows positive EPS, historical EPS figures were negative, indicating a recovery phase rather than a consistent profitability track record.

Summary: CorMedix is showing encouraging signs of a financial turnaround in Q1 2025, with revenue growth, positive net income, EPS improvement, and stronger cash flow from operations. However, investors should be cautious given the historical losses, high expenses, and operational liabilities. The company’s increased cash reserves and capital raises have strengthened the balance sheet, providing some buffer to fund ongoing development and marketing efforts. Continued monitoring of profitability and cash flow trends will be important to assess sustainability.

10/15/25 09:05 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About CorMedix's Financials

When does CorMedix's fiscal year end?

According to the most recent income statement we have on file, CorMedix's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has CorMedix's net income changed over the last 10 years?

CorMedix's net income appears to be on an upward trend, with a most recent value of -$17.93 million in 2024, falling from -$20.45 million in 2014. The previous period was -$46.34 million in 2023. Find out what analysts predict for CorMedix in the coming months.

What is CorMedix's operating income?
CorMedix's total operating income in 2024 was -$22.36 million, based on the following breakdown:
  • Total Gross Profit: $40.28 million
  • Total Operating Expenses: $62.64 million
How has CorMedix's revenue changed over the last 10 years?

Over the last 10 years, CorMedix's total revenue changed from $189.27 thousand in 2014 to $43.47 million in 2024, a change of 22,867.9%.

How much debt does CorMedix have?

CorMedix's total liabilities were at $34.19 million at the end of 2024, a 186.9% increase from 2023, and a 2,236.4% increase since 2014.

How much cash does CorMedix have?

In the past 10 years, CorMedix's cash and equivalents has ranged from $4.34 million in 2014 to $53.32 million in 2021, and is currently $40.65 million as of their latest financial filing in 2024.

How has CorMedix's book value per share changed over the last 10 years?

Over the last 10 years, CorMedix's book value per share changed from 0.16 in 2014 to 1.44 in 2024, a change of 786.0%.


Related Companies

This page (NASDAQ:CRMD) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners
URGENT: The Market's 3 Red Flags Are Flashing
Here’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...
StockEarnings | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Arizona-made nanochips the new millionaire maker?
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...
Banyan Hill Publishing | Sponsoredtc pixel
Buy UBER immediately
BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...
Chaikin Analytics | Sponsoredtc pixel
Front-Run Buffett's Shocking Gold Move
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...
Golden Portfolio | Sponsoredtc pixel
$15 Fund: Turn Gold Boom into Real Income
If you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...
Investors Alley | Sponsoredtc pixel
Forget AI, This Will Be the Next Big Tech Breakthrough
After picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...
Brownstone Research | Sponsoredtc pixel
Trump’s new nightmare begins
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsoredtc pixel